We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$432M
AUM Growth
+$52.5M
Cap. Flow
+$99.1M
Cap. Flow %
22.96%
Top 10 Hldgs %
72.69%
Holding
32
New
3
Increased
10
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$66.8M
2
MRUS
Merus
MRUS
+$22.1M
3
BLU
BELLUS Health Inc.
BLU
+$20.7M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$15.3M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$9.72M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$26.1M
2
KURA icon
Kura Oncology
KURA
+$18.7M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.95M
5
RVMD icon
Revolution Medicines
RVMD
+$6.22M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$53.8M 12.46%
3,217,163
+467,026
+17% +$7.65M
MRUS
2
DELISTED
Merus
MRUS
$47.7M 11.04%
1,498,890
+780,754
+109% +$22.1M
ACRS icon
3
Aclaris Therapeutics
ACRS
$730M
$38.9M 9%
2,672,346
+482,055
+22% +$7.3M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$34.1M 7.89%
1,090,126
+510,694
+88% +$15.3M
CYTK icon
5
Cytokinetics
CYTK
$11B
$32.1M 7.44%
704,537
-92,041
-12% -$3.55M
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.75B
$27.6M 6.38%
805,573
+307,494
+62% +$9.72M
BLU
7
DELISTED
BELLUS Health Inc.
BLU
$25.2M 5.83%
+3,124,613
New +$20.7M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$19.6M 4.53%
2,281,315
+368,804
+19% +$3.21M
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$18.3M 4.24%
5,419,896
+1,250,000
+30% +$4.75M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$16.8M 3.88%
847,683
+180,009
+27% +$3.35M
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$16.7M 3.87%
3,711,286
+592,525
+19% +$3.01M
VTGN icon
12
VistaGen Therapeutics
VTGN
$9.29M
$16.5M 3.82%
282,167
+111,383
+65% +$7.25M
CCCC icon
13
C4 Therapeutics
CCCC
$376M
$15.5M 3.59%
481,094
– –
CELC icon
14
Celcuity
CELC
$4.03B
$12.1M 2.81%
920,464
– –
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.9M 2.76%
+1,247,043
New +$8.04M
TNYA icon
16
Tenaya Therapeutics
TNYA
$168M
$9.74M 2.26%
513,930
– –
ALLK
17
DELISTED
Allakos
ALLK
$7.99M 1.85%
+815,667
New +$66.8M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$4.13M 0.96%
312,553
– –
KRON
19
DELISTED
Kronos Bio
KRON
$4.06M 0.94%
298,839
– –
DYN icon
20
Dyne Therapeutics
DYN
$4.04B
$3.63M 0.84%
305,125
– –
IVA
21
Inventiva
IVA
$1.05B
$3.59M 0.83%
262,658
– –
GNCA
22
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.57M 0.83%
3,079,756
– –
MREO
23
Mereo BioPharma
MREO
$45.9M
$3.13M 0.72%
1,954,970
-17,988
-0.9% -$36K
PMVP icon
24
PMV Pharmaceuticals
PMVP
$66.1M
$2.89M 0.67%
125,000
– –
BLSA
25
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.45M 0.57%
250,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Commodore Capital held 32 positions worth $432M, up 14% from $379M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Commodore Capital deployed $99.1M of net new capital in Q4 2021, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Allakos: 815,667 shares worth $7.99M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $3.55M trimmed.

  • Commodore Capital's largest Q4 2021 buy was Allakos: 815,667 shares worth $7.99M.
  • Commodore Capital added most to Merus in Q4 2021, an estimated $22.1M increase.
  • Commodore Capital's biggest Q4 2021 reduction was Cytokinetics, cutting an estimated $3.55M.
  • Commodore Capital fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $26.1M.
  • Commodore Capital's ten largest holdings make up 73% of its $432M portfolio in Q4 2021.
  • Commodore Capital opened 3 new positions and closed 7 in Q4 2021.
  • Commodore Capital's portfolio value rose 14% quarter-over-quarter to $432M.

Based on Commodore Capital's 13F filing for Q4 2021, filed 14 Feb 2022.